Table 3

Frequencies of different cell populations in SLE patients and healthy controls

Cell population

Healthy controls (median and 95% CI)1

SLE patients (median and 95% CI)

P-value


CD3+ T cells

60.9 (57.8 to 63.9)

65.1 (55.7 to 64.3)

0.42

CD4+ T cells

62.1 (57.0 to 64.7)

55.2 (51.3 to 58.9)

0.06

CD4+HLA-DR+

6.5 (5.3 to 7.2)

31.3 (24.9 to 36.9)

0.001

CD8+ T cells

15.7 (14.3 to 18.8)

20.4 (18.6 to 24.0)

0.02

CD8+HLA-DR+

40.8 (39.0 to 43.2)

36.9 (33.4 to 41.5)

0.33

BDCA-1+ mDCs

0.40 (0.34 to 0.46)

0.31 (0.28 to 0.62)

0.19

BDCA-2+ pDCs

0.07 (0.07 to 0.11)

0.09 (0.09 to 0.16)

0.39

CD14++CD16- monocytes

10.1 (9.6 to 13.3)

16.9 (16.0 to 25.2)

0.013

CD14++CD16+ monocytes

0.17 (0.15 to 0.27)

0.30 (0.44 to 0.81)

0.003

CD19+ B cells

5.6 (4.7 to 6.3)

5.1 (5.0 to 7.8)

0.78

CD19+CD27+IgD-CD38+CD20-

0.43 (0.35 to 0.75)

1.0 (0.8 to 3.0)

< 0.0001


1For CD3+ T cells, dendritic cells, monocytes and B cells the percentage is calculated against the total leukocyte count. For all subpopulations, the percentage is calculated against the main population (for example, CD4+ T cells for all CD4+ T cell analyses).

CI, confidence interval; HLA, human leukocyte antigen; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell

Lood et al. Arthritis Research & Therapy 2011 13:R60   doi:10.1186/ar3314

Open Data